Fundraising FoxRejuvenate Bio
San Diego, US · Delaware corporation · 8 known investors
Find your way into Rejuvenate Bio
Sign up to see every warm intro you have to Rejuvenate Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Rejuvenate Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Rejuvenate Bio develops gene therapy treatments aimed at the root causes of aging to address chronic, age-related conditions such as osteoarthritis, heart disease, and cancer. It targets both companion animals (particularly dogs) and humans.
Founders & leadership
ND
Noah DavidsohnCSO and cofounderNoah Davidsohn earned a Ph.D. in biological engineering from MIT and a B.S. in Applied Physics from Caltech, with postdoctoral training in George Church's lab at Harvard Medical School focused on genome modification technologies. He is Co-Founder and Chief Scientific Officer of Rejuvenate Bio, which develops gene therapies and epigenetic approaches to treat age-related diseases in both humans and companion animals.
DO
Daniel OliverCEO and FounderDaniel Oliver is co-founder and CEO of Rejuvenate Bio, a gene therapy company developing treatments for age-related diseases in animals and humans that emerged from work in George Church's lab at Harvard Medical School. He previously co-founded and led Voxel8, a 3D printed electronics company spun out of the Wyss Institute, through product launch and its acquisition by Kornit.
GC
George ChurchCo-Founder and SABGeneral Partner & Investment Committee Member at Kendall Capital Partners
DA
Deborah AscheimChief Medical OfficerDr. Ascheim is Chief Medical Officer at Rejuvenate Bio, where she leads clinical development strategy and trial execution. She brings three decades of experience in clinical medicine and research, including prior roles as Chief Medical Officer at StrideBio and Capricor Therapeutics, faculty positions in cardiology at Columbia University and Mount Sinai, and leadership of clinical trial units and consulting work focused on gene therapies and complex disease development.
Board
DZ
Investors · 8
Companion Fundlisted by Companion FundNew York
How we know: Companion Fund's portfolio page · Not right? Tell us
Connecticut Innovationslisted by Connecticut InnovationsNew Haven · $500K – $2M
How we know: Connecticut Innovations's portfolio page · offering press articles · Not right? Tell us
Digitalis Ventureslisted by Digitalis VenturesNew York · $100K – $10M
How we know: Digitalis Ventures's portfolio page · a partner's Signal profile · press coverage · Not right? Tell us
__Twitter.png)
Kendall Capital Partnerslisted by Kendall Capital PartnersBoston
How we know: Kendall Capital Partners's portfolio page · offering press articles · press coverage · Not right? Tell us
Lifespan Vision Ventureslisted by Lifespan Vision VenturesNorwalk
How we know: Lifespan Vision Ventures's portfolio page · Not right? Tell us
KdT VenturesreportedAustin · $500K – $3M
How we know: funding news · press coverage · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$34M disclosed across 2 rounds · 2021–2026
▶$19.5MraisedJun 2026 · 35 investors · BiotechnologyRule 506(b)
▶$19.5MraisedJun 2026 · 35 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
- Noah DavidsohnExecutive Officer, Director
- David ZhuDirector
- Daniel OliverExecutive Officer, Director
- Offering amount
- $27M
- Amount sold
- $19.5M
- Minimum investment
- $20K
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.6MraisedApr 2021 · 22 investors · BiotechnologyRule 506(b)
▶$14.6MraisedApr 2021 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel OliverExecutive Officer, Director
- Noah DavidsohnExecutive Officer, Director
- Offering amount
- $15.3M
- Amount sold
- $14.6M
- Minimum investment
- $10K
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Rejuvenate Bio went on to found or lead other companies.
Related companies · 5
Life BiosciencesLife Biosciences is a biopharmaceutical company developing therapies focused on aging and age-related diseases, working across gene therapy and neuroscience programs. It advances drug candidates from discovery through clinical development.
LifespanLifespan Research Institute invests in biotechnology startups developing regenerative medicine and longevity therapies. The institute funds companies working on age-related disease treatment, including cellular senescence, tissue damage repair, and cancer therapeutics.
bioBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Rejuvenation Technologies Inc.Rejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.
Regeneron NASDAQ: REGN www.regeneron.comRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Companies working in the same space as Rejuvenate Bio.
Non-dilutive funding · 8 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseSpecial Operations Command | Phase II | 2022 | $3M |
| Department of DefenseSpecial Operations Command | Phase IISTTR | 2021 | $2.1M |
| Department of DefenseSpecial Operations Command | Phase II | 2020 | $1.4M |
| Department of DefenseSpecial Operations Command | Phase IISTTR | 2019 | $1.4M |
| Department of DefenseSpecial Operations Command | Phase II | 2018 | $1.4M |
| Department of DefenseSpecial Operations Command | Phase I | 2018 | $150K |
| Department of DefenseSpecial Operations Command | Phase ISTTR | 2018 | $149.9K |
| Department of DefenseSpecial Operations Command | Phase I | 2018 | $99.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Rejuvenate Bio do?
- Rejuvenate Bio develops gene therapy treatments aimed at the root causes of aging to address chronic, age-related conditions such as osteoarthritis, heart disease, and cancer. It targets both companion animals (particularly dogs) and humans.
- Who founded Rejuvenate Bio?
- Rejuvenate Bio was founded by Noah Davidsohn, Daniel Oliver, George Church.
- Who are Rejuvenate Bio's investors?
- Rejuvenate Bio's investors include Companion Fund, Connecticut Innovations, Digitalis Ventures, Gaingels, Kendall Capital Partners, Lifespan Vision Ventures, VCapital, KdT Ventures.
- How much funding has Rejuvenate Bio raised?
- Rejuvenate Bio has disclosed $34M raised across 2 rounds.
- Where is Rejuvenate Bio headquartered?
- Rejuvenate Bio is headquartered in San Diego, US.